Compare Lowe`s Companies Inc (LOW) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Philip Morris International Inc. — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 2.9× Lowe`s Companies Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Philip Morris International Inc. for 85 Days on average.
| LOW | PM | |
|---|---|---|
Market Cap | $105.96B | $312.50B |
Volume | 4,039,547 | 5,517,172 |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $287.39 | $200.50 |
52-Week Low | $179.50 | $144.33 |
Typical Hold Time | 98 Days | 85 Days |
Enterprise Value | $144.81B | $355.62B |
Dividend Yield | 2.65% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with recent earnings beats but faces a bearish technical outlook. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue declined to $83.67B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector contends with a slowing housing market.
Wall Street maintains a bullish consensus with a $244.09 price target (60.8% buy ratings), but risks include high debt levels and economic sensitivity. The stock offers value with dividend payments, yet investors must weigh competitive pressures and macroeconomic headwinds against its innovation efforts and market position.
Philip Morris International (PM) trades at $200.5, up 4.05% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and revenue growth is robust, driven by smoke-free products like IQOS and ZYN. The stock is near its pivot point of $200, with support at $197 and resistance at $203. Cash flow trends show improving operational performance, though debt levels remain elevated.
The outlook is positive due to earnings momentum and smoke-free product expansion, but risks include regulatory pressures and high valuation. Wall Street consensus is bullish with a $212.17 price target, suggesting upside potential. Investors should weigh growth prospects against macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
